Trials / Withdrawn
WithdrawnNCT03546400
Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
A Phase 4, Open-label, Safety, Tolerability And Pharmacokinetic Study Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 48 Months – 69 Months
- Healthy volunteers
- Not accepted
Summary
2-week open-label safety, tolerability and pharmacokinetic study of methylphenidate HCl ERCT in 4-5 year old children with ADHD.
Detailed description
Phase 4, Open-label, Safety, Tolerability And Pharmacokinetic Study Of methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablets (ERCT) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (ADHD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | methylphenidate HCl ERCT | methylphenidate HCl ERCT |
Timeline
- Start date
- 2018-09-25
- Primary completion
- 2020-12-03
- Completion
- 2020-12-03
- First posted
- 2018-06-06
- Last updated
- 2018-11-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03546400. Inclusion in this directory is not an endorsement.